Search
sumifilam
Indications:
- investigational agent for treatment of Alzheimer's disease
Dosage:
- 50 mg or 100 mg BID
Mechanism of action:
- binds to filamin A Clinical trials.
- phase 2b trial [1]
- improves entire panel of validated biomarkers
- improves episodic memory & spatial working memory vs placebo (46-17%)
Notes:
- investigator indicted on charges of research fraud used to obtain NIH funding [2]
General
pharmaceutical agents for treatment of Alzheimer's disease (Alzheimer's agent)
References
- Cassava Sciences. Sept 14, 2020
Cassava Sciences Announces Final Results of a Phase 2b Clinical Study
of Sumifilam in Patients with Alzheimer's Disease.
https://www.globenewswire.com/news-release/2020/09/14/2092861/0/en/Cassava-Sciences-Announces-Final-Results-of-a-Phase-2b-Clinical-Study-of-Sumifilam-in-Patients-with-Alzheimer-s-Disease.html
- Bush E
Scientist behind Alzheimer's drug in late-stage trials is indicted on charges
of research fraud.
Science News. June 28, 2024
https://www.nbcnews.com/science/science-news/scientist-alzheimers-drug-candidate-indicted-charges-research-fraud-rcna159537